Tag: GlobeNewswire

Acquisition Adds an Established Subscription-Based Food Commerce Business, Recurring Revenue Model and Proprietary Technology Platform to Tritent’s Growing Portfolio

LAS VEGAS, Oct. 05, 2026 (GLOBE NEWSWIRE) — Tritent International Corp. (OTCID: TICJ) (“Tritent” or the “Company”) today announced that its wholly owned Ontario subsidiary has entered into a definitive agreement to acquire 100% of the issued and outstanding shares of Super Fresh Foods Inc., owner and operator of AllYourMeals.com, a subscription-based prepared meal company supported by a proprietary digital commerce platform designed to manage recurring customer relationships, online ordering and scalable fulfillment operations.

The acquisition represents an important milestone in Tritent’s strategy of acquiring established operating businesses with scalable business models, recurring revenue potential, proprietary technology and experienced leadership.

Following closing, Super Fresh Foods Inc. will become an indirect wholly owned subsidiary of Tritent International Corp., adding an operating subscription business with years of commercial experience and proprietary digital infrastructure designed to support long-term growth.

Entering One of the Fastest Growing Segments of Food Commerce

Consumer demand for prepared meals, subscription services and direct-to-consumer food delivery continues to expand as consumers increasingly prioritize convenience, healthier eating and recurring purchasing.

According to Grand View Research, the global online food delivery market exceeded US$380 billion in 2024 and is expected to continue growing throughout the coming decade.

At the same time, Fortune Business Insights estimates the global meal-kit and prepared meal delivery market will continue to experience strong growth as consumers increasingly adopt subscription-based purchasing models and recurring home delivery.

Management believes these trends are driving a structural shift toward recurring digital food commerce, creating attractive opportunities for businesses capable of combining food production, technology and customer engagement within a scalable operating platform.

An Operating Business Built Around Recurring Revenue

Unlike traditional food ordering marketplaces, AllYourMeals.com has been developed as a subscription-based prepared meal business supported by proprietary digital commerce technology.

While customers may place individual orders, the Company’s core business model emphasizes recurring meal subscriptions designed to create long-term customer relationships and recurring revenue.

The business combines an established prepared meal operation with a proprietary digital commerce platform supporting:

• Subscription management
• Recurring customer ordering
• One-time purchases
• Customer acquisition
• Customer communications
• Menu management
• Production planning
• Order management
• Packing and fulfillment
• Delivery coordination

Management believes this integrated operating model provides a scalable foundation for future expansion while allowing the Company to continuously improve operational efficiencies and customer experience.

More Than a Concept—An Established Operating Business

Management believes one of the most compelling aspects of this acquisition is that Tritent is acquiring an established operating business rather than an early-stage concept.

Super Fresh Foods has accumulated years of operational experience serving customers through its prepared meal business while continually refining its technology platform, production processes and customer engagement model.

The Company believes this operating history provides a meaningful foundation upon which to pursue future growth initiatives.

Through the acquisition Tritent acquires substantially all operating assets associated with Super Fresh Foods and AllYourMeals.com, including those conveyed under the transaction documents, such as intellectual property, proprietary software, databases, trademarks, domain names, websites, social media assets, customer-related assets and associated goodwill.

Leadership with Entrepreneurial Vision

The acquisition also brings the operating and entrepreneurial experience of Benny Doro, founder of Super Fresh Foods Inc. and All Your Meals.

Doro has led the development of the Company’s subscription-based direct-to-consumer prepared meal business while overseeing the creation of its proprietary digital commerce, customer management and fulfillment platform.

Management believes his operational experience and industry knowledge will play an important role in the continued growth of the business.

Creating Long-Term Shareholder Value

Tritent believes the acquisition creates multiple opportunities for future growth, including:

Expansion of digital food commerce services;

Strategic partnerships with restaurants and food brands;

Increased consumer engagement through technology;

Development of recurring revenue opportunities;

International expansion initiatives; and

Additional acquisitions that complement the Company’s growing portfolio.

The Company believes the addition of an operating digital platform further diversifies its business while creating opportunities to expand revenues through multiple complementary channels.

A Foundation for Future Growth

“This acquisition represents another important milestone in Tritent’s long-term growth strategy,” said Reno J. Calabrigo, Chief Executive Officer of Tritent International Corp.

“We’re excited to welcome Benny and the All Your Meals team to Tritent. What attracted us to this opportunity wasn’t simply a website—it was an established operating business with recurring customers, proprietary technology and years of operating experience. We believe businesses built around recurring revenue and scalable digital infrastructure represent compelling long-term opportunities, and this acquisition aligns well with Tritent’s strategy of building a diversified portfolio of operating companies capable of creating sustainable shareholder value.”

Benny Doro, Founder of Super Fresh Foods Inc., added:

“Joining Tritent gives us an opportunity to accelerate the growth of All Your Meals. We’ve spent years developing the operating experience behind the business and have built a subscription-based platform designed to support recurring customer relationships, ordering, production and fulfillment at scale. Tritent’s resources can help us accelerate the next stage of that growth while continuing to improve the experience we provide our customers.”

Looking Ahead

The Company expects to continue evaluating additional strategic acquisitions that complement its long-term vision of building a diversified portfolio of operating businesses with scalable revenue opportunities.

Management believes this acquisition represents another important step in Tritent’s long-term strategy of building a diversified portfolio of scalable operating businesses.

As the Company continues to execute this strategy, management expects to pursue opportunities that complement its existing operations while evaluating additional acquisitions, strategic partnerships and organic growth initiatives designed to strengthen the Company’s long-term competitive position.

About Tritent International Corp.

Tritent International Corp. (OTCID: TICJ) is focused on identifying, acquiring and developing businesses with scalable operating models, innovative technologies and long-term growth potential. Through disciplined acquisitions and strategic partnerships, the Company seeks to build a diversified portfolio of businesses designed to create sustainable long-term shareholder value.

About Super Fresh Foods Inc.

Super Fresh Foods Inc. is the owner and operator of AllYourMeals.com, a subscription-based prepared meal company supported by a proprietary digital commerce platform. The business combines recurring meal subscriptions, one-time ordering and technology designed to manage customer acquisition, subscription management, production planning, fulfillment and delivery. For additional information about Super Fresh Foods Inc., please visit:

Website: company.allyourmeals.com & allyourmeals.com

Forward-Looking Statements

This press release contains forward-looking statements regarding the anticipated benefits of the acquisition, future business plans, growth opportunities, industry trends and expected operating performance. These statements are based on current expectations and involve risks and uncertainties, including integration risks, market conditions, customer adoption, financing, competition, regulatory matters and other factors that could cause actual results to differ materially. Readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update these statements except as required by applicable law.

For more information, please contact:

Tritent International Corp.
Email: info@tritentintlcorp.com

Schouw & Co. share buy-back programme, week 40 2026

On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026. As outlined in Company Announcement no. 48 of 14 August 2026, the programme was extended with up to DKK 170 million, increasing the total amount of which Schouw & Co. will acquire shares to up to DKK 410 million.

The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).

Trading day	No. of shares	Average price	Amount DKK
Accumulated until 25 September 2026	470,041	705.04	331,398,272
Monday, 28 September 2026	5,900	813.00	4,796,700
Tuesday, 29 September 2026	5,500	807.27	4,440,000
Wednesday, 30 September 2026	5,000	804.50	4,022,500
Thursday, 1 October 2026	5,000	790.21	3,951,027
Friday, 2 October 2026	5,000	799.04	3,995,208
In the period 28 September 2026 – 2 October 2026	26,400	803.24	21,205,435
Accumulated until 2 October 2026	496,441	710.26	352,603,707
Following the above transactions, Schouw & Co. holds a total of 2,794,234 treasury shares corresponding to 11.18% of the total share capital of 25,000,000 shares.

Aktieselskabet Schouw & Co.

Jørgen Dencker Wisborg, Chairman
Jens Bjerg Sørensen, President, telephone number +45 86 11 22 22

Attachments

• SBB2026 Week 40
• 2026-10-05 FBM26-60 SBB-w40 ENG

AS Nordecon group company Embach Ehitus OÜ and the Estonian University of Life Sciences have entered into a contract for the design and reconstruction of blocks 3 and 5 of the academic building at Kreutzwaldi 56 in Tartu. The contract value is EUR 5.6 million, excluding VAT. The works are scheduled for completion in November 2027.

Nordecon (www.nordecon.com) is a group of construction companies whose core business is construction project management and general contracting in the buildings and infrastructures segment. Geographically the Group operates in Estonia, Ukraine and Sweden. The parent of the Group is Nordecon AS, a company registered and located in Tallinn, Estonia. The consolidated revenue of the Group in 2025 was 208 million euros. Currently Nordecon Group employs 450 people. Since 18 May 2006 the company’s shares have been quoted in the main list of the Nasdaq Tallinn Stock Exchange.

Andri Hõbemägi
Nordecon AS
Head of Investor Relations
Tel: +372 6272 022
E-mail: andri.hobemagi@nordecon.com
www.nordecon.com

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities (PDMR)/person closely associated with them (PCA)
a)	Name	William Roberts
2	Reason for the notification
a)	Position/status	Non-Executive Director/PDMR
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Admiral Group plc
b)	LEI	213800FGVM7Z9EJB2685
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares GB00B02J6398
b)	Nature of the transaction	Acquisition of shares pursuant to a dividend reinvestment trading plan entered into on 25 May 2022.
c)	Prices(s) and volume(s)	Price(s)	Volume(s)
		USD$48.66	206
d)	Aggregated information Aggregated value Price	N/A (Single Transaction)
e)	Date of the transaction	2 October 2026
f)	Place of the transaction	New York Stock Exchange (NYSE)

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — Serve Robotics Inc. (Nasdaq: SERV), a leader in autonomous robotics, announced that on Wednesday, October 7, 2026, Ali Kashani, Co-Founder and Chief Executive Officer, and Brian Read, Chief Financial Officer, will host one-on-one meetings with investors at Evercore ISI’s 5th Annual Automation Tech & Physical AI Conference in New York.

Investors interested in connecting with Serve management at the conference may contact investors.relations@serverobotics.com.

For more information, please visit the Company’s Investor Relations website at investors.serverobotics.com.

About Serve

Serve Robotics (Nasdaq: SERV) designs and operates autonomous robots that navigate complex, human-centric environments. Since spinning off from Uber in 2021, Serve has deployed more than 2,000 robots across the U.S., reaching a population of approximately 3 million and supporting delivery for more than 4,000 restaurants. In 2026, Serve acquired Diligent Robotics, expanding its operations beyond sidewalk delivery into indoor service robots used in hospitals. Serve designs both the hardware and software behind its robots, enabling them to work safely in public and private environments at scale.

For more information, visit www.serverobotics.com or follow the company on X, Instagram, and LinkedIn @serverobotics.

Forward Looking Statements

This press release contains “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the context of the statement and generally arise when we or our management are discussing our beliefs, estimates or expectations. Such statements generally include the words “believes,” “plans,” “intends,” “targets,” “may,” “could,” “should,” “will,” “expects,” “estimates,” “suggests,” “anticipates,” “outlook,” “continues,” or similar expressions. These statements are not historical facts or guarantees of future performance, but represent management’s belief at the time the statements were made regarding future events which are subject to certain risks, uncertainties and other factors, many of which are outside of our control. Actual results and outcomes may differ materially from what is expressed or forecast in such forward-looking statements.

The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in our filings with the Securities and Exchange Commission (“SEC”), including in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2025, as supplemented by the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and in the Company’s subsequent SEC filings. The Company can give no assurance that the plans, intentions, expectations or strategies as reflected in or suggested by those forward-looking statements will be attained or achieved. The forward-looking statements in this press release are based on information available to the Company as of the date hereof, and the Company disclaims any obligation to update any forward-looking statements, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage of the antiviral potential of Ampligen^® (rintatolimod), the Company’s investigational dsRNA and highly selective TLR3 agonist immunomodulator.

• Healthcare Business Today: AIM ImmunoTech CEO Tom Equels on Why Broad-Spectrum Antiviral Preparedness Cannot Wait for the Next Outbreak
• MediTech Today: What AIM ImmunoTech’s New Long COVID Patent Protection Says About the Future of Post-Viral Therapeutics

The recent coverage reflects growing attention around Ampligen’s potential broad-spectrum antiviral and biodefense preparedness applications, including the drug’s possible role against emerging viral and post-viral threats such as Ebola Virus Disease, as well as the continued expansion of AIM’s intellectual property portfolio in Long COVID and other antiviral applications.

The coverage has emphasized the broad-spectrum antiviral potential of Ampligen, which research shows enhances the body’s innate immune response, enabling it to fight back against a diverse range of viral threats – and perhaps even stave off initial infections by dangerous diseases. Clinical trials suggest that Ampligen’s broad-spectrum immune effect is also the reason for its potential as a therapy against a range of solid tumors, including pancreatic cancer, which is the focus of AIM’s oncology clinical program.

“I am a true believer in the proposition that a strong innate response is vitally important,” said AIM Chief Executive Officer Thomas K. Equels. “Recent media coverage underscores the important role that a broad-spectrum antiviral such as Ampligen could serve in preparing for potential viral threats before they grow into very real outbreaks. We believe Ampligen’s broad-spectrum antiviral potential, together with the continued expansion of our intellectual property estate in Long COVID and other post-viral applications, supports a differentiated opportunity across preparedness and public health. We remain focused on advancing the body of evidence around Ampligen and protecting its potential applications.”

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen^® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include statements relating, but not limited to: the potential of Ampligen to address viral and post-viral threats, and the Company’s ability to create long-term value for its stockholders. Forward-looking statements include statements attributed to, or made by, the Company’s Chief Executive Officer in this press release. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. Words such as “believe,” “may,” “might,” “will,” “could,” “should,” “can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “envision,” “potential” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

For a detailed discussion of these and other risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. These filings are available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only.

CONTACT: Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million

Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range

EDEN PRAIRIE, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced preliminary, unaudited product revenue for its fourth fiscal quarter and full fiscal year ended September 30, 2026, and provided an update on recent product orders.

NeuroOne expects to report fourth quarter fiscal 2026 product revenue of approximately $3.8 million, representing year-over-year growth of 38.4%, compared to approximately $2.7 million in the fourth quarter of fiscal 2025. For the full fiscal year 2026, the Company expects to report revenue of approximately $10.5 million, representing 15.6% year-over-year growth and landing at the top of its previously announced revenue guidance range of $9.2 million to $10.5 million.

In September 2026, NeuroOne secured a $4.5 million product purchase order, the largest in the Company’s history. Approximately $1.0 million of the order shipped in September 2026, with shipments of the remaining $3.6 million expected to begin during the first quarter of fiscal 2027 and into the second quarter of fiscal 2027, subject to manufacturing and delivery schedules. Following receipt of this order, total open purchase orders for shipments through the first quarter of fiscal 2027 increased to $5.4 million as of September 30, 2026. This record purchase order provides greater visibility into anticipated product shipments, cash flow and revenue opportunities as the Company enters fiscal 2027.

“Momentum continues to build across our business,” said Dave Rosa, Chief Executive Officer of NeuroOne. “We are happy to report that product orders increased 24.2% in fiscal 2026 compared to fiscal 2025. We enter fiscal 2027 from a position of strength supported by $5.4 million in open purchase orders and we are also very well positioned with additional growth drivers including the commercialization of our trigeminal neuralgia system, international market expansion, and the advancement of our drug delivery platform.”

Complete financial results for the fourth quarter and full fiscal year 2026 are expected to be announced in December 2026, in conjunction with the filing of the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission.

The selected unaudited financial results included in this press release are preliminary and subject to the completion of year-end accounting and audit procedures and are therefore subject to adjustment. This preliminary financial information is the responsibility of management and has been prepared in good faith on a basis consistent with prior periods. As a result, prospective investors should exercise caution in relying on this information and should not draw any inferences regarding the Company’s financial information that is not provided. This preliminary financial information should not be viewed as a substitute for complete financial statements prepared in accordance with United States generally accepted accounting principles.

About NeuroOne

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue”, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the fourth quarter and full fiscal year 2026 revenue amounts, international market expansion, and the launch of our drug delivery program. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages, risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks related to our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

Company Contact:
800-631-4030
ir@nmtc1.com

Investor Relations:
MZ Group – MZ North America
949-491-8235

NMTC@mzgroup.us

BALTIMORE, Oct. 05, 2026 (GLOBE NEWSWIRE) — Sinclair, Inc. (Nasdaq: SBGI) will report its third quarter 2026 earnings results at 4:00 p.m. ET on Wednesday, November 4, 2026, followed by a conference call to discuss the results at 4:30 p.m. ET.

The call will be webcast live and can be accessed at www.sbgi.net under the subtitle “Investor Relations/Events and Presentations.” The dial-in number for the earnings call is 877-545-0523, with entry code 437861.

If you plan to participate on the conference call, please call at least two minutes prior to the start time and provide the entry code to the conference operator; or tell the operator that you are joining the Sinclair Earnings Conference Call.

If you are unable to listen to the live webcast or participate in the live conference call, a replay of the call will be available on Sinclair’s website at www.sbgi.net. This will be the only venue through which a replay will be available. The company’s press release and any non-GAAP reconciliations will also be available on the website.

Members of the news media are welcome on the call in a listen-only mode. Key executives will be made available to members of the news media, time permitting, following the conference call.

The Company regularly uses its website as a key source of Company information and can be accessed at www.sbgi.net.

Category: Financial

Investor Contacts:

Christopher C. King, VP, Investor Relations

(410) 568-1500

Stockholm, 5th of October 2026 – Virtune AB (Publ) (“Virtune”) today announces that it has completed the monthly rebalancing of the Virtune Crypto Altcoin Index ETP, listed on Nasdaq Stockholm, Nasdaq Helsinki, Xetra and Warsaw Stock Exchange (ISIN code SE0023260716).

In addition to the Virtune Crypto Altcoin Index ETP, Virtune’s product portfolio includes:

Virtune Arbitrum ETP
Virtune Avalanche ETP
Virtune Bitcoin ETP
Virtune Bitcoin Prime ETP
Virtune Bittensor ETP
Virtune BNB ETP
Virtune Chainlink ETP
Virtune Coinbase 50 Index ETP
Virtune Crypto Top 10 Index ETP EUR
Virtune Crypto Top 10 Index ETP SEK
Virtune Hyperliquid ETP
Virtune Litecoin ETP
Virtune Polygon ETP
Virtune Stablecoin Index ETP
Virtune Staked Cardano ETP
Virtune Staked Ethereum ETP
Virtune Staked NEAR ETP
Virtune Staked Polkadot ETP
Virtune Staked Solana ETP
Virtune Stellar ETP
Virtune Sui ETP
Virtune XRP ETP

Index allocation as of 29 September 2026 (before rebalancing):

Bitcoin Cash: 11.11%
Chainlink: 11.08%
Solana: 10.86%
Cardano: 10.07%
Stellar: 9.91%
XRP: 9.79%
Canton: 9.78%
Hyperliquid: 9.47%
BNB: 9.26%
Gram: 8.68%

Index allocation as of 30th of September (after rebalancing):

Canton: 10.00%
Cardano: 10.00%
Bitcoin Cash: 10.00%
BNB: 10.00%
Solana: 10.00%
Stellar: 10.00%
XRP: 10.00%
Hyperliquid: 10.00%
Chainlink: 10.00%
Litecoin: 10.00%

In connection with this month’s rebalancing, Gram (GRAM) is exiting the index and Litecoin (LTC) is entering the index.

The performance of the Virtune Crypto Altcoin Index ETP for September was +15.39%.

The rebalancing is carried out according to the index that the ETP tracks, the Virtune Crypto Altcoin Index. The purpose of the monthly rebalancing is to reset the weights of each crypto asset to provide equal-weighted exposure to altcoins.

Virtune Crypto Altcoin Index ETP is the first of its kind in the Nordic region. It includes up to 10 leading alternative crypto assets (altcoins), excluding Bitcoin and Ethereum. Each altcoin is equally weighted to promote diversification; this structure allows investors to gain broad exposure to crypto assets beyond Bitcoin and Ethereum without being heavily concentrated in any single crypto asset.

If you, as an (institutional) investor, are interested in meeting with Virtune to explore how our ETPs can support your asset management strategy or to learn more about Virtune and our product offering, please feel free to contact us at hello@virtune.com. You can also visit www.virtune.com to learn more and subscribe to our newsletter for updates on upcoming ETP launches and other news related to digital assets.

Press contact
Christopher Kock, CEO Virtune AB (Publ)
christopher@virtune.com
+46 70 073 45 64

Virtune with its headquarters in Stockholm is a regulated Swedish digital asset manager and issuer of crypto exchange traded products on regulated European exchanges. With regulatory compliance, strategic collaborations with industry leaders and our proficient team, we empower investors on a global level to access innovative and sophisticated investment products that are aligned with the evolving landscape of the global crypto market.

Cryptocurrency investments are associated with high risk. Virtune does not provide investment advice. Investments are made at your own risk. Securities may increase or decrease in value, and there is no guarantee that you will recover your invested capital. Please read the prospectus, KID, terms at www.virtune.com.

Pilot follows extensive adaptation of the Jupiter product line to meet end customer-specific video streaming requirements, with potential for broader deployment

Rehovot, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global leader in edge computing, artificial intelligence (“AI”), and video intelligence solutions for defense applications, today announced that it has received a pilot order for an armored vehicle situational awareness application from a leading global defense company. The order was received through a distributor.

The pilot follows an extensive engineering and adaptation process in which Maris-Tech’s Jupiter product line was adapted to meet the end customer’s specific video streaming requirements for armored vehicle situational awareness.

The adaptations developed to address these requirements have expanded the capabilities of Maris-Tech’s products that the Company believes may also support additional applications and market opportunities across the modern battlefield.

Based on estimates and forecasts provided by the end customer, successful completion of the pilot could result in significant follow-on orders over the coming years.

“This pilot represents the result of a substantial engineering process focused on meeting the specific video requirements of a major defense customer,” said Israel Bar, Chief Executive Officer of Maris-Tech. “We believe that beyond the potential opportunity with this customer, the capabilities developed through this process strengthen the versatility of our Jupiter product line and expand its relevance to additional armored vehicle and battlefield applications.”

About Maris-Tech Ltd.

Maris-Tech delivers AI-powered edge video solutions for mission-critical defense and security operations, enabling real-time situational awareness, intelligence gathering, and surveillance in bandwidth- and latency-constrained environments. Trusted by leading security organizations, Maris-Tech platforms are deployed across UAVs, UGVs, armored vehicles, and dismounted soldier systems, supporting missions that require ultra-low-latency video processing and onboard AI analytics. From intelligence collection in extreme conditions to AI-driven surveillance and terrain dominance, Maris-Tech masters the AI video pipeline at the edge through best-in-class SWaP-optimized, ruggedized computing solutions.

For more information, visit https://www.maris-tech.com/

Forward-Looking Statements Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect” “may”, “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it is discussing the advantages, benefits and capabilities of the Jupiter product line, its belief that the added capabilities of the Jupiter product line may also support additional applications and market opportunities across the modern battlefield, the potential for successful completion of the pilot to result in significant follow-on orders over the coming years and the Company’s belief that beyond the potential opportunity with this customer, the capabilities developed through this process strengthen the versatility of its Jupiter product line and expand its relevance to additional armored vehicle and battlefield applications. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: its ability to successfully market its products and services, including in the United States; the acceptance of its products and services by customers; its continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; its ability to successfully develop new products and services; its success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; its ability to comply with applicable regulations; and the other risks and uncertainties described in the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on May 15, 2026, and its other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations:

Nir Bussy, CFO
Tel: +972-72-2424022
Nir@maris-tech.com